Warning: The NCBI web site requires JavaScript to function. more...
Novel therapies in genitourinary cancer: an update.
Chu D, Wu S.
J Hematol Oncol. 2008 Aug 11;1:11. Review.
Related citations
Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A.
BJU Int. 2007 Feb;99(2):274-80. Epub 2006 Dec 1. Review.
Novel therapies in breast cancer: what is new from ASCO 2008.
Chu D, Lu J.
J Hematol Oncol. 2008 Oct 1;1:16. Review.
American Society of Clinical Oncology 41st annual meeting.
Dillman RO.
Expert Opin Biol Ther. 2005 Aug;5(8):1117-27. Review.
Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE, Figlin RA.
Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190. Review.
Novel therapeutics for metastatic renal cell carcinoma.
Cancer. 2009 May 15;115(10 Suppl):2361-7. Review.
Recent developments in renal cell cancer immunotherapy.
Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A.
Expert Opin Biol Ther. 2007 May;7(5):727-37. Review.
Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B.
Drugs. 2007;67(9):1257-64. Review.
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Mendoza L.
Klin Onkol. 2009;22(4):131-8. Review.
Targeted therapies for kidney cancer in urologic practice.
Haas NB, Uzzo RG.
Urol Oncol. 2007 Sep-Oct;25(5):420-32. Review.
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Moldawer NP, Figlin R.
Oncol Nurs Forum. 2008 Jul;35(4):699-708. Review.
Systemic therapy for metastatic renal cell carcinoma.
Kroog GS, Motzer RJ.
Urol Clin North Am. 2008 Nov;35(4):687-701; ix. Review.
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Speca J, Yenser S, Creel P, George D.
Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S24-30. Review.
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
Aktuelle Urol. 2009 Jan;40(1):31-6. Epub 2009 Jan 28. German.
Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A, Merseburger AS.
Rev Recent Clin Trials. 2008 Sep;3(3):212-6. Review.
Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S.
Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. Review.
Highlights from the Society of Urologic Oncology 4th annual meeting.
Coleman J, Franks ME, Grubb RL 3rd, Wynberg J, Lee CS, Behari A, Kim CM, Williams C, Linehan WM.
J Urol. 2005 Mar;173(3):938-41.
Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK, Mughal TI, Rini BI.
Clin Genitourin Cancer. 2006 Sep;5(2):110-3. Review.
EGFR-targeted therapies in colorectal cancer.
Overman MJ, Hoff PM.
Dis Colon Rectum. 2007 Aug;50(8):1259-70. Review.
Molecularly targeted therapies for breast cancer.
Hobday TJ, Perez EA.
Cancer Control. 2005 Apr;12(2):73-81. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on